Track topics on Twitter Track topics that are important to you
In what seems like some consolation for Daiichi Sankyo after its disastrous acquisition of Ranbaxy Laboratories and subsequent divestment of the Indian company, arbitration proceedings in Singapore ag...
An arbitration panel found the former controlling stakeholders of Ranbaxy concealed information when they sold the firm to Daiichi Sankyo.
Sun Pharmaceuticals has confirmed it will close a Ranbaxy Laboratories facility in Ireland by the end of the year.
The two former owners of India's Ranbaxy Laboratories have been ordered to pay $385 million to Daiichi Sankyo Co., the Japanese pharmaceutical company that bought the drugmaker in 2008.
The former owners of Indian drugmaker Ranbaxy have been ordered to pay Daiichi Sankyo $385m for concealing quality problems across its manufacturing network before selling the business.
India’s Sun Pharmaceutical recently rolled out its first OTC drug, antacid Pepmelt, as it leverages the consumer healthcare portfolio acquired in its Ranbaxy Laboratories buy.
India's Sun Pharma has clinched a deal to sell a US plant as part of a consolidation drive in the wake of its purchase of rival Ranbaxy, amid improving investor sentiment toward the country's biggest ...
MUMBAI (Reuters) - The former owners of Indian drugmaker Ranbaxy Laboratories have been ordered by an arbitration court to pay damages worth 25.63 billion rupees ($385 million) to Japan's Daiichi Sank...
The study was undertaken to evaluate the effect of Quercetin on the pharmacokinetics of Atorvastatin Calcium. In-vivo Pharmacokinetic studies were performed on rats in a single dose study and multiple...
The interaction of atorvastatin with bovine serum albumin (BSA) was investigated using multi-spectroscopic methods and molecular docking technique for providing important insight into further elucidat...
Few data are present in the literature on the relationship between atorvastatin use and acute pancreatitis. The aim of this study was to explore this issue in Taiwan.Using representative claims data e...
The use of atorvastatin is rapidly increasing among statins since the introduction of generics. However, only limited data are available on its current use and the effectiveness outside of randomised ...
Atorvastatin reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe (EZE) , a nonstatin drug that reduces intestinal chol...